Wasilewska Anna, Taranta-Janusz Katarzyna, Zoch-Zwierz Walentyna, Rybi-Szumińska Agnieszka, Kołodziejczyk Zbigniew
Klinika Pediatrii i Nefrologii, Uniwersytet Medyczny w Białymstoku.
Przegl Lek. 2009;66(9):485-90.
Metalloproteinases (MMP) and their tissue inhibitors (TIMP) play a crucial role to keep the balance between the synthesis and degradation of extracellular matrix protein. Balance disturbances of those two systems lead to abnormal tissue remodeling. There is evidence that matrix metalloproteinases activity changes in many pathological conditions, including inflammatory, degenerative disorders as well as tumor progression. Recent investigations indicate that MMPs and TIMPs play a pivotal role in pathogenesis of most of kidney diseases. Studies describing dysregulated activity of MMPs and/or their tissue inhibitors in various experimental and clinical models of kidney disease, including chronic kidney disease, glomerulonephritis, pyelonephritis, diabetic and hypertensive nephropathy, polycystic kidney disease and renal cancer are reviewed.
金属蛋白酶(MMP)及其组织抑制剂(TIMP)在维持细胞外基质蛋白合成与降解之间的平衡中起着关键作用。这两个系统的平衡紊乱会导致组织重塑异常。有证据表明,在许多病理状况下,包括炎症、退行性疾病以及肿瘤进展,基质金属蛋白酶的活性都会发生变化。最近的研究表明,MMP和TIMP在大多数肾脏疾病的发病机制中起关键作用。本文综述了在各种肾脏疾病的实验和临床模型中,包括慢性肾病、肾小球肾炎、肾盂肾炎、糖尿病和高血压肾病、多囊肾病以及肾癌,关于MMP及其组织抑制剂活性失调的研究。